Microbot Medical (NASDAQ:MBOT – Get Free Report) and NexGel (NASDAQ:NXGL – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Microbot Medical and NexGel, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Microbot Medical | 1 | 1 | 2 | 1 | 2.60 |
| NexGel | 1 | 0 | 1 | 0 | 2.00 |
Microbot Medical presently has a consensus price target of $6.62, suggesting a potential upside of 270.11%. NexGel has a consensus price target of $2.00, suggesting a potential upside of 348.93%. Given NexGel’s higher probable upside, analysts plainly believe NexGel is more favorable than Microbot Medical.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Microbot Medical | N/A | N/A | -$13.14 million | ($0.26) | -6.88 |
| NexGel | $11.42 million | 0.36 | -$3.00 million | ($0.40) | -1.11 |
NexGel has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than NexGel, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 2.2% of NexGel shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by company insiders. Comparatively, 23.4% of NexGel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Microbot Medical has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, NexGel has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.
Profitability
This table compares Microbot Medical and NexGel’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Microbot Medical | N/A | -21.84% | -20.71% |
| NexGel | -28.54% | -64.29% | -29.64% |
Summary
Microbot Medical beats NexGel on 9 of the 14 factors compared between the two stocks.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
About NexGel
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
